Last Updated on November 27, 2025 by Bilal Hasdemir

Acute myeloid leukemia (AML) is a fast-growing cancer that affects the blood and bone marrow.At Liv Hospital,we understand how serious this disease is and its big impact on patients’ lives.

Abnormal, immature blood cells build up in the bone marrow. This stops normal blood cell production. Researchers are working on new treatments like targeted therapies and stem cell transplants to help AML patients.

We are dedicated to giving top-notch care and the newest treatment methods to AML patients. Our team works hard to offer full support and care that fits each patient’s needs.

Key Takeaways

• AML is a rapidly progressing blood cancer that affects the bone marrow.
• Abnormal blood cells interfere with normal blood cell production.
• Targeted therapies and stem cell transplantation are being used to improve AML outcomes.
• Liv Hospital provides complete care and personalized attention to AML patients.
• Our team is committed to delivering world-class treatment and support.

Understanding Blood Cancer Basics

It’s important to know the basics of blood cancer to understand acute leukemia. Blood cancer, like leukemia, happens when blood cell production goes wrong. This is because of problems in the bone marrow.

The Role of Bone Marrow in Blood Production

Bone marrow is the soft tissue in bones like hips and thighbones. It makes blood cells. It creates:

• Red blood cells that carry oxygen
• White blood cells that fight infections
• Platelets that help blood clot

How Blood Cells Normally Develop

Blood cells start from stem cells in the bone marrow. This is called hematopoiesis. It’s a complex process where stem cells turn into different blood cells.

Usually, the bone marrow makes cells that work well. But with leukemia, this process goes wrong.

Cell Type	Function	Abnormality in Leukemia
Red Blood Cells	Carry oxygen	Reduced count leading to anemia
White Blood Cells	Fight infections	Overproduction of immature cells
Platelets	Aid in blood clotting	Reduced count leading to bleeding

Research is going on for treatments like CER-1236 for Acute Myeloid Leukemia (AML). Knowing how blood cells work helps us understand leukemia’s effects. It also shows the promise of new treatments.

What Is Acute Leukemia Cancer

Acute leukemia cancer is a blood cancer that makes lots of immature blood cells fast. This messes up how blood cells are made in the bone marrow. It causes many health problems.

Definition and Classification

Acute leukemia is when too many immature blood cells, called blasts, fill the bone marrow and blood. These cells can’t work right. They take over, causing trouble. It’s split into two main types based on the cell type and how mature they are.

There are two main types: Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL). AML affects cells that make red blood cells, platelets, and some white blood cells. ALL affects cells that help fight off infections.

How Acute Leukemia Differs from Chronic Leukemia

Acute leukemia is very different from chronic leukemia. Chronic leukemia grows slowly, letting more mature cells be made. But acute leukemia grows fast, with lots of immature cells.

Chronic leukemia starts slowly, with symptoms taking months or years to show. But acute leukemia can make symptoms appear quickly, needing fast medical help.

New treatments for acute leukemia, like AML, are showing promise. For example, Auron Therapeutics is working on AUTX-703, a new drug for AML and other blood cancers. These new ideas show we’re getting better at treating acute leukemia.

Characteristics	Acute Leukemia	Chronic Leukemia
Progression	Rapid and aggressive	Slow and gradual
Cell Maturity	Immature cells (blasts)	More mature cells
Symptoms Onset	Sudden	Gradual over months or years

Types of Acute Leukemia

There are mainly two types of acute leukemia: Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL). Each type has its own traits and treatment methods.

Acute Myeloid Leukemia (AML)

AML starts in the bone marrow and quickly spreads to the blood. It can also reach other areas like the lymph nodes, liver, spleen, and even the brain. AML is marked by fast-growing abnormal cells that block the bone marrow from making normal blood cells. New treatments, like CER-1236 by CERo Therapeutics, are being tested to help patients.

Acute Lymphoblastic Leukemia (ALL)

ALL is a fast-moving blood cancer that affects lymphoid cells. It quickly worsens if not treated. ALL is the most common cancer in kids, but it can also hit adults. Treatment often includes chemotherapy, targeted therapy, and sometimes a stem cell transplant.

Knowing the differences between AML and ALL is key to finding the right treatment. Both are aggressive, but their unique features need specific therapy plans.

Acute Myeloid Leukemia (AML) Explained

Acute Myeloid Leukemia (AML) is a serious blood cancer. It needs quick diagnosis and treatment. We’ll explore what AML is, its traits, and how it’s diagnosed.

Definition and Characteristics

AML starts in the bone marrow and quickly spreads to the blood. It can also reach other areas like the lymph nodes and liver. The disease makes abnormal white blood cells grow fast, crowding out normal cells.

Key characteristics of AML include:

• The presence of myeloid blasts in the bone marrow or blood
• A high rate of cell proliferation
• Inhibition of normal hematopoiesis

The 20% Blast Threshold for Diagnosis

Diagnosing AML involves finding at least 20% myeloid blasts in the bone marrow or blood. The World Health Organization (WHO) set this rule. This rule helps tell AML apart from other blood disorders.

Alternative Names: Acute Myelocytic Leukemia and ANL Leukemia

AML is also called acute myelocytic leukemia and acute non-lymphocytic (ANL) leukemia. These names are often used together. Knowing these names can help in understanding treatment plans.

New studies show hope for AML treatment. For example, AUTX-703 has shown promise in early tests. This gives patients new hope.

Epidemiology of AML

The study of AML’s spread gives us important info on its occurrence and who gets it. Knowing this helps in planning health efforts and finding the best ways to help people.

Incidence and Prevalence in the United States

Every year, AML strikes nearly 19,940 people in the U.S. It’s a big health issue. The disease doesn’t affect everyone equally; it depends on age and other factors.

Age-adjusted incidence rates show how AML affects people of different ages. The latest numbers show most cases happen in people over 65.

Age and Demographic Distribution

AML is more common with age. The average age when people find out they have it is about 68. It also happens a bit more in men than women.

Knowing who gets AML helps in making better screening plans. It also helps in making sure everyone has access to the care they need.

Risk Factors for Developing AML

Knowing the risk factors for Acute Myeloid Leukemia (AML) is key for early detection and prevention. Several factors can make someone more likely to get AML.

Genetic Predispositions

Genetics play a big role in AML. Certain genetic disorders, like Down syndrome, Fanconi anemia, and Bloom syndrome, raise the risk. Also, having a family history of leukemia can increase your risk.

Genetic Syndromes Associated with AML:

• Down syndrome
• Fanconi anemia
• Bloom syndrome
• Ataxia-telangiectasia

Environmental Exposures

Being exposed to certain environmental factors can raise your risk of AML. Benzene, found in gasoline and used in industry, and ionizing radiation from nuclear accidents or medical treatments are examples.

Environmental Factor	Description	Risk Level
Benzene exposure	Chemical found in gasoline and industrial processes	High
Ionizing radiation	Exposure from nuclear accidents or certain medical treatments	High
Pesticide exposure	Exposure to certain pesticides	Moderate

Prior Medical Treatments

Some medical treatments can increase your risk of AML. This includes chemotherapy with alkylating agents or topoisomerase II inhibitors, and radiation therapy. People who have had cancer treatment before are at higher risk of secondary AML.

By knowing these risk factors, we can aim for early detection and lower AML incidence through prevention.

Recognizing AML Symptoms

Spotting AML symptoms early is vital for better treatment and survival. It’s tough to recognize them because they can be vague. But knowing the common signs helps people get medical help fast.

Common Physical Symptoms

AML affects blood cell production, leading to various physical symptoms. Some common ones include:

• Pain or discomfort in the bones or joints
• Swollen lymph nodes
• Enlarged liver or spleen
• Pale skin

Fatigue and Weakness

Fatigue is a common symptom of AML. It’s a feeling of constant weakness and lack of energy. This usually happens because of anemia, caused by fewer red blood cells.

Increased Infections, Bruising, and Bleeding

AML can make you more likely to get infections. It also lowers platelets, leading to bruising and bleeding easily. These signs are urgent and need quick medical care.

Here’s a quick summary of AML symptoms:

Symptom	Description
Fatigue	Persistent weakness and lack of energy
Increased Infections	Frequent infections due to low white blood cell count
Bruising and Bleeding	Easy bruising and bleeding due to low platelet count

How AML Differs from ALL

AML and ALL are two types of acute leukemia. They differ in where they start and how they are treated. Knowing these differences is key for the right diagnosis and treatment.

Cell Origin Differences

AML comes from myeloid cells. These cells make red blood cells, platelets, and some white blood cells. ALL, on the other hand, starts in lymphoid cells. These cells turn into lymphocytes, a type of white blood cell important for fighting off infections.

Age Distribution Variations

AML can happen at any age but is more common in adults over 60. ALL, while also found in adults, is more common in children. This age difference affects how the disease is treated and the patient’s outlook.

Treatment Approach Distinctions

AML treatment often includes strong chemotherapy followed by more therapy or a stem cell transplant. The treatment plan depends on the patient’s age, health, and the leukemia’s genetic makeup. ALL treatment starts with strong chemotherapy to get the disease into remission. Then, there’s consolidation and maintenance therapy. The intensity and length of treatment depend on the patient’s risk level.

Characteristics	AML	ALL
Cell Origin	Myeloid cells	Lymphoid cells
Common Age Group	Adults (60+ years)	Children
Treatment Approach	Intensive chemotherapy, consolidation therapy, stem cell transplant	Induction chemotherapy, consolidation, maintenance therapy

Understanding the differences between AML and ALL helps doctors create better treatment plans. This improves the patient’s chances of a good outcome and a better quality of life.

Diagnosis and Classification of AML

Diagnosing AML needs a detailed approach. This includes blood tests, bone marrow biopsy, and cytogenetic analysis. We will look at the different ways to diagnose and classify AML.

Blood Tests and Bone Marrow Biopsy

The first step is blood tests to check blood cell counts. A complete blood count (CBC) is done to see if there are abnormal white, red blood cells, and platelets.

Next, a bone marrow biopsy is done. This involves taking a sample from the hipbone. It’s then checked under a microscope for cancer cells.

• Blood tests help identify abnormal blood cell counts.
• Bone marrow biopsy provides detailed information about the marrow’s cellular structure.

Cytogenetic and Molecular Testing

Cytogenetic testing looks at the genetic material of cancer cells. It examines the chromosomes for any abnormalities.

Molecular testing finds specific genetic mutations in AML. Techniques like polymerase chain reaction (PCR) and next-generation sequencing (NGS) are used.

“Cytogenetic and molecular testing play a vital role in diagnosing AML and determining the prognosis.”

— A Hematologist

The WHO and FAB Classification Systems

The World Health Organization (WHO) and the French-American-British (FAB) classification systems are key for AML classification.

Classification System	Description
WHO Classification	Considers genetic and clinical features for classification.
FAB Classification	Focuses on the cell type and level of differentiation.

These systems help find the specific AML subtype. This is important for choosing the right treatment.

Using these systems helps tailor treatments for each patient. This improves AML care outcomes.

Current Treatment Approaches for AML

Today, AML treatment combines induction, consolidation, and sometimes stem cell transplantation. These methods aim to get patients into remission and improve their chances of survival.

Induction Therapy

Induction therapy is the first step in treating AML. It uses strong chemotherapy to kill cancer cells in the bone marrow.

Key components of induction therapy include:

• High-dose chemotherapy
• Supportive care to manage side effects

Consolidation Therapy

After induction therapy, consolidation therapy aims to get rid of any leftover leukemia cells. This phase is key for long-term remission.

Consolidation therapy may involve:

• Additional chemotherapy cycles
• Stem cell transplantation in eligible patients

Stem Cell Transplantation

Stem cell transplantation is a possible cure for AML, mainly for those with high-risk disease or relapse. It replaces the patient’s bone marrow with healthy stem cells.

Types of stem cell transplantation include:

• Autologous transplantation (using the patient’s own stem cells)
• Allogeneic transplantation (using donor stem cells)

Targeted Therapies

Targeted therapies are becoming a big part of AML treatment. They focus on specific genetic mutations or proteins that help leukemia cells grow.

Examples of targeted therapies include:

• FLT3 inhibitors for patients with FLT3 mutations
• IDH1 and IDH2 inhibitors for patients with IDH1 or IDH2 mutations

Treatment Approach	Description	Key Benefits
Induction Therapy	Initial chemotherapy to induce remission	Rapid reduction in leukemia cells
Consolidation Therapy	Additional treatment to eliminate remaining leukemia cells	Improved long-term remission rates
Stem Cell Transplantation	Replacing patient’s bone marrow with healthy stem cells	Potential cure for AML
Targeted Therapies	Treatments targeting specific genetic mutations or proteins	Personalized treatment approach

Prognosis and Multidisciplinary Care

Understanding AML prognosis and the role of multidisciplinary care teams is key to better patient outcomes. At Liv Hospital, we focus on a team-based approach for AML management. This ensures our patients get the best care possible.

Survival Rates and Prognostic Factors

AML patient prognosis varies based on age, genetic mutations, and treatment response. Survival rates have grown thanks to new treatments. We look at different prognostic factors to find the best treatment for each patient.

Age is a big factor, with older patients facing tougher challenges. Genetic mutations like FLT3 and NPM1 also affect prognosis and treatment choices.

The Importance of Multidisciplinary Care

Effective AML management needs a multidisciplinary care team. This includes hematologists, oncologists, radiologists, and supportive care specialists. At Liv Hospital, our teams work together to create personalized treatment plans for each patient.

Our teams make sure patients get top-notch medical care and support. This holistic approach is vital for better patient outcomes and quality of life.

By understanding prognosis and getting care from a multidisciplinary team, AML patients can manage their treatment better. We’re dedicated to providing world-class healthcare and support for our international patients, including those with AML.

Conclusion

Acute Myeloid Leukemia (AML) is a complex and challenging condition. It needs complete care and support. We’ve looked at what AML is, how it’s classified, and how it’s diagnosed.

We’ve also talked about the different treatments for AML. These include induction therapy, consolidation therapy, and stem cell transplantation.

Advances in AML treatment and care are making a big difference. Targeted therapies and personalized medicine are key in managing this disease. It’s important to provide complete care and support to AML patients.

A team of experts is essential in helping patients with AML. By understanding the risks, recognizing symptoms, and using current treatments, we can improve AML patient outcomes. Our goal is to offer top-notch healthcare and support to international patients seeking advanced medical treatments.

FAQ

Reference

NCBI. Research. https://www.ncbi.nlm.nih.gov/books/NBK560490/

Patient Power. AML vs. ALL: What Are the Key Differences? https://patientpower.info/leukemia/aml-vs-all